Navigation Links
DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Date:4/16/2008

t inhibitor of secretory phospholipase A2(sPLA2) activity, including groups IIA, V, and X. The U.S. Food and Drug Administration granted A-001 orphan drug status for the prevention of acute chest syndrome in patients with sickle cell disease in December 2007.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co., Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family - a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes, prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel, upstream steps in the inflammation cascade and have the potential to address a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com.

MEDIA CONTACT:

Anne Bowdidge (650) 218-6900

pr@anthera.com


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
2. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
3. DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
4. DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
5. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
6. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
7. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
8. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... GLASGOW, Scotland , July 24, 2014 Cancer ... will gain access to state-of-the-art cancer treatment closer to home ... next year. Varian Medical Systems (NYSE: ... and an order was placed in June for four TrueBeam™ ... TrueBeam systems, which offer fast and efficient radiotherapy and radiosurgery ...
(Date:7/24/2014)... July 24, 2014 Second Quarter ... President and Chief Executive Officer effective September 2, 2014 ... $20.4 million , BioGlue ® revenues grew ... ® revenues grew 22 percent year-over-year to $1.1 ... 20 percent year-over-year to $1.7 million , Tissue ...
(Date:7/24/2014)... Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: ... it has filed a detailed complaint with the ... (NYSE: AGN ) apparent attempts to ... price of Valeant,s common shares by continuing to ... despite Valeant,s public statements correcting this misinformation. A ...
Breaking Medicine Technology:Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 2CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 4CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 5CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 6CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 7CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 8CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 9CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 10CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 11CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 12CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 13CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 14CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 15CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 16CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 17Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 4Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 5Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 6
... YORK, Feb. 15, 2012 Delcath Systems, Inc. (NASDAQ: ... ( Instituto Europeo di Oncologia – IEO) introduced ... a Feb. 15 press conference and discussed the status ... CHEMOSAT is a critical new treatment option for patients ...
... ERT (NASDAQ: ERT ) announced today that it ... year 2011 Monday, February 27, after the market closes. After ... 5:00 PM ET that day. For the conference ... United States or 1-412-858-4600 when calling internationally. There will be ...
Cached Medicine Technology:Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 2Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 3Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 4ERT to Report Fourth Quarter and Full Year 2011 Operating Results 2
(Date:7/24/2014)... July 24, 2014 CarePoint Health ... in hematology and oncology, Dr. Hitendra Upadhyaya, has ... system welcomes Dr. Upadhyaya to the community. Hundreds ... Health Medical Group, a comprehensive network of top ... wide range of specialties. This latest acquisition represents ...
(Date:7/24/2014)... Pools and beaches are the place to be on ... for small children, so Amica Insurance is sharing ... Centers for Disease Control and Prevention, children between the ages ... injuries and deaths. It’s important to know the best practices ... offering the following tips from the American Red Cross:, ...
(Date:7/24/2014)... This year the Walk to End Alzheimer’s in ... Life, will be held on Saturday, September 20 in Denver ... Run at 7:50 am, the untimed 5k Run at 8 ... Walk to End Alzheimer’s unites the entire community in a ... this devastating disease, “stated Linda Mitchell, CEO and president of ...
(Date:7/24/2014)... a foreign material like a medical device or surgical ... always responds. According to Northwestern University,s Guillermo Ameer, most ... affect the device,s function. , "You will always get ... of biomedical engineering in Northwestern,s McCormick School of Engineering ... Feinberg School of Medicine. "A problem with commonly used ...
(Date:7/24/2014)... Researchers at Le Bonheur Children,s Hospital and the ... a clinical trial of a new drug shown to ... healthy adult volunteers intranasally infected with respiratory syncytial virus ... respiratory tract infections in young children in the United ... the labs of Infectious Disease Specialist John DeVincenzo, MD. ...
Breaking Medicine News(10 mins):Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:Antioxidant biomaterial promotes healing 2Health News:RSV research breakthrough to help infected children 2
... 4 Nu Skin Enterprises, Inc. (NYSE: NUS ... quarterly dividend of $0.115 per share, which will be paid ... 15, 2009. , , The Company , ... its tradition of innovation through its comprehensive anti-aging product portfolio, ...
... planned benefit changes , , PORTLAND, Ore., June 4 ... perfect storm of rising health care costs and the declining ... three years of predictable rate adjustments and planned benefit changes, ... economic uncertainties. , , In these trying ...
... DIEGO, June 4 NuVasive, Inc. (Nasdaq: NUVA ... minimally disruptive surgical treatments for the spine, announced today that ... to present at the 8th Annual Needham Life Sciences Conference ... York, on Thursday, June 11, 2009, at 11:00 a.m. Eastern ...
... violent relationship may lead to poor mental health, ... --Adults who witnessed parental violence while growing up ... according to researchers who studied 3,023 adults in ... current depression, as well as their experiences with ...
... - , , - Total Net Sales in Line with Previous ... Today at 3:30 pm Central Time - , ... a medical device company that develops, manufactures and markets innovative proprietary products ... and full year ended March 31, 2009. Net sales of $2.9 ...
... is proud to announce the four finalists for its ... a competition to find Minnesota,s most innovative and effective ... cash awards as part of the Engaged Philanthropy Conference ... Graves 601 Hotel in Minneapolis. The Social Entrepreneur,s Cup ...
Cached Medicine News:Health News:Regence Rate Assure(SM) Offers Employer Groups Guaranteed Rates, Benefits 2Health News:NuVasive to Present at the 8th Annual Needham Life Sciences Conference 2Health News:NuVasive to Present at the 8th Annual Needham Life Sciences Conference 3Health News:When Parents Fight, Children Often End Up With Scars 2Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 2Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 3Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 4Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 5Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 6Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 7Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 8Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 9Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 10Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 11Health News:Social Entrepreneur's Cup Finalists Announced 2Health News:Social Entrepreneur's Cup Finalists Announced 3Health News:Social Entrepreneur's Cup Finalists Announced 4Health News:Social Entrepreneur's Cup Finalists Announced 5
... Raintree Billing Manager and Collections ... centralized or de-centralized billing models and ... collection ratios with the ability to ... single claims more directly from the ...
Visionary OFFICE™ PM offers a Windows interface featuring medical billing, appointment scheduling and patient information....
A.I.med's medical billing software is a medical billing software. The billing module integrates with A.I.med's Electronic Medical Record software. A.I.med's medical billing module also integrates wit...
... system allows a practice to manage ... integrated with the EMR, appointment system ... with electronic clearinghouses for electronic claim ... of reports, it presents practice management ...
Medicine Products: